pre|CISION® Platform · FAP-Targeted Oncology · What's Confirmed, What's Coming, and When
Avacta is a clinical-stage AIM biotech developing pre|CISION® — a peptide drug conjugate (PDC) platform that uses fibroblast activation protein (FAP), an enzyme overexpressed in the tumour microenvironment of ~90% of solid tumours, to cleave an inert drug-peptide conjugate and release active chemotherapy directly at the tumour site. Two assets are in the clinic: AVA6000 (faridoxorubicin, FAP-released doxorubicin) and AVA6103 (FAP-Exd, FAP-released exatecan). This report replaces the earlier long-form deep research document — the platform's core scientific and mechanistic questions are now settled by clinical data; what matters from here is a small number of concrete near-term events.
AVA6000 has FDA agreement on a single pivotal trial design with PFS as the sole endpoint for full approval in salivary gland cancer (SGC) — no confirmatory trial burden. Clinical data (92% DCR, 4 confirmed PRs in 38 SGC patients, zero cardiac toxicity in 111 patients) is presented and published. The platform's core scientific risk — does FAP-cleavage work in humans, including at low FAP expression — is answered, in both AVA6000 (yes, confirmed via biopsy and FAPI-PET) and, pending, AVA6103. Avacta will not run the AVA6000 pivotal trial without a partner — stated three times in RNS this year. The board is now fully assembled around deal execution. The market has not re-rated to reflect any of this. The next 5 months contain several dated, checkable events plus one large unscheduled one (a partnership deal).
These are no longer open questions. Each is backed by a specific, dated, public disclosure.
Direct tumour biopsy data (AACR/ESMO 2024, n=11): mean 860 ng/gm doxorubicin in tumour vs 8.3 ng/ml in plasma — 117:1 median ratio (up to 278:1). Published in Annals of Oncology. This is measured drug concentration in human tissue, not a model.
BIO International RNS (25 Jun 2026): n=26 biopsies, two independent statistical methods (FAP IHC + tri-colour immunofluorescence) — no relationship between FAP expression level and tumour response. FAPI-PET sub-study: FAP expression persists despite deep tumour response, meaning the enzyme stays available for cleavage even in strong responders. This directly explains why the drug still works in FAP-low tumours and supports the platform's applicability to the ~90% of solid tumours expressing FAP at any level.
PopPK modelling presented at ASCO (1 Jun 2026): the sharp systemic Cmax peaks that cause conventional doxorubicin cardiotoxicity are eliminated by the FAP-cleavage mechanism itself. Zero cardiomyopathy events of any grade in 111 patients dosed, including patients at cumulative exposures equivalent to 550mg/m² (~3× the conventional lifetime limit). FDA agreed to remove the lifetime dose cap on this basis.
RNS 25 June 2026: single pivotal study, PFS as sole primary endpoint, full approval (not accelerated — no mandatory post-approval confirmatory trial). First- and second-line patients in the most prevalent SGC subtypes. This is a materially shorter and lower-risk regulatory path than the two-trial (Phase 2 → Phase 3) structure that would otherwise apply.
ASCO formal presentation (1 Jun 2026), first author Renata Ferrarotto (MD Anderson): 92% disease control rate in 38 evaluable SGC patients; 4 confirmed partial responses + 9 minor responses; pivotal-aligned cohort (n=32, rarer subtypes excluded) shows 4 confirmed PRs + 8 confirmed MRs with median PFS not yet mature. Historical benchmark for pre-treated SGC: ~3.5 month PFS. Published: J Clin Oncol 44, 2026 (suppl 16; abstr e15113).
The 25 June RNS explicitly disclosed a positive STS signal ("tumor responses are also observed") in the same release while saying only that the TNBC cohort "continues and data will be reported when mature" — no response data of any kind. This asymmetry is worth tracking, not glossing over. Do not treat TNBC as "STS's sibling, just a bit behind" — treat it as a genuine unknown until data is disclosed.
Reading: a board this densely weighted toward pharma-exit experience, capital-markets execution, and NASDAQ governance is not typical for a company this size. It is consistent with — but does not confirm — active preparation for either a partnership/acquisition process or a NASDAQ dual listing (the Toppan Merrill F-1 prospectus specialist engagement, disclosed in the FY25 Annual Report back-matter, points the same direction).
Everything below is either a confirmed date (drawn from ESMO's published congress calendar or explicit company guidance) or an unscheduled item flagged because the pre-conditions for it are now in place. Ordered chronologically.
The framing "nothing happens until AVA6103 data at year-end" understates the calendar. At least one guided data delivery (FAPI-PET) is confirmed for Q3, ESMO gives two hard checkable dates (17 Jul, 25 Sep), TNBC/STS maturation is realistically a Q3 event, and a partnership deal is a live possibility at any point given every stated pre-condition is now in place. AVA6103 data remains the largest single catalyst, but it is not the only one on the board.
Deliberately kept short. These are the specific, checkable unknowns worth tracking — not a generic risk list.
No data disclosed either way as of 14 July 2026. The 25 June RNS's silence on TNBC, immediately next to a disclosed STS positive, is worth watching closely when data does mature.
Every stated pre-condition is now in place (FDA agreement, BIO meetings held, board assembled). No confirmed timeline exists publicly. Genuinely could be weeks or could extend into 2027.
Trial expansion and new hires since guidance was set have modestly increased the cost base. "Early Q1 2027" likely still holds but with a thinner buffer than the headline suggests — a further raise or royalty-financing action before year-end would not be surprising.
Preclinical data showed strong tumour-selectivity vs Enhertu/Datroway. Whether this replicates in human tissue at the doses used in FOCUS-01 is the single largest unresolved scientific question left on the platform.
Full valuation methodology (rNPV build, TAM by indication, M&A comparables) is unchanged in substance from prior analysis — the figures below are the current headline outputs, not a re-derivation.
150–300p rNPV, reflecting FDA-agreed pivotal pathway, confirmed low-FAP activity, and a ~40% platform-calibrated probability of success (vs a standard ~25% for an unproven mechanism) given the delivery mechanism is independently validated across two clinical assets.
£800M–£1.5bn single-bidder floor (105–200p) — but this would likely be rejected by a board this stacked with M&A experience. A competitive process implies £3–6bn (380–760p); with a defensive bidder present (AZ protecting Enhertu/Datroway share), £6–12bn (760–1,520p).
Novartis paid $1.1bn upfront + $400M milestones for a private UK ADC biotech with a novel payload (NMTi) but conventional antibody-based targeting and no disclosed human proof-of-concept. Avacta has clinical validation in 111+ humans, an FDA-agreed full-approval pathway, and definitive human proof its mechanism works even in antigen/target-low tumours — the exact limitation antibody-based ADCs like Myricx's still carry. On a like-for-like basis, Avacta's floor should sit meaningfully above this figure.
At 68.5p (£323M), the stock prices in essentially zero probability of a competitive acquisition and does not yet reflect the FDA pivotal agreement or BIO platform data in any analyst model. The stock has now slipped below the 72p consensus target — a reversal from early July, when it briefly traded above consensus. Either read is telling: trading above stale consensus implied the market was ahead of unrevised analyst models; trading below it now suggests either profit-taking after the run to 89p, or the market pricing in the cash-runway/TNBC uncertainty flagged in Section 5 rather than the FDA/BIO positives from Section 2.
This is not a binary science bet. The core mechanistic questions — does FAP-cleavage delivery work in humans, does it work at low FAP expression, is the cardiac safety real — are answered, with data, across two independent clinical assets. What remains open is commercial and financial: whether and when a partner signs, whether the cash runway holds with the margin implied, and whether AVA6103's human PK data confirms what AVA6000's already has.
The board has been rebuilt over the past three months specifically around deal-execution capability — a chairman from the company's own broker, a deputy chairman with a personal $9.5bn pharma-exit precedent and current NASDAQ board experience, an active HCRx advisor, a CFO who has executed a NASDAQ listing before. None of this guarantees a deal or a listing on any particular timeline. It does mean the infrastructure for one is now fully in place, at the same moment the FDA has removed the largest remaining regulatory uncertainty from the lead asset.
The next five months contain more checkable, dated events than the "wait for year-end" framing suggests — two hard ESMO abstract dates (17 Jul, 25 Sep), a guided Q3 mechanistic data delivery (FAPI-PET), an open TNBC question that will resolve one way or the other, and one large unscheduled event (a partnership deal) for which every stated pre-condition is now satisfied.
⚠️ This report is for informational and research purposes only. It does not constitute financial advice and should not be used as the sole basis for any investment decision. Clinical-stage biotech investments carry a high risk of loss, including total loss of capital. Clinical trial outcomes are unpredictable. Past share price performance is not a reliable indicator of future results. The company may need to raise further equity on terms dilutive to existing shareholders. Always conduct your own research and consider consulting an authorised financial adviser before making investment decisions. Nothing in this report constitutes a personal recommendation to buy or sell any security. Data as of 14 July 2026, share price ~79p. I am an AI assistant, not a licensed financial professional.